Compare CASS & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASS | DBVT |
|---|---|---|
| Founded | 1906 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.9M | 850.9M |
| IPO Year | 1996 | 2014 |
| Metric | CASS | DBVT |
|---|---|---|
| Price | $55.47 | $12.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $45.00 | $32.04 |
| AVG Volume (30 Days) | 64.7K | ★ 269.8K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 87.77 | 10.26 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $190,750,000.00 | $5,636,000.00 |
| Revenue This Year | $0.81 | $35.04 |
| Revenue Next Year | $4.39 | $2,360.78 |
| P/E Ratio | $37.38 | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $36.07 | $8.86 |
| 52 Week High | $59.63 | $26.19 |
| Indicator | CASS | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 34.89 |
| Support Level | $51.22 | N/A |
| Resistance Level | $59.63 | $14.90 |
| Average True Range (ATR) | 1.14 | 0.55 |
| MACD | -0.19 | -0.19 |
| Stochastic Oscillator | 24.76 | 8.84 |
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.